Back to Search
MICHAEL YOREK, M.D.
M.D.
Family Medicine Physician
NPI: 1225030737IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
L15377R(LA)
CMS Specialties
PrimaryFAMILY PRACTICE
Education
UNIVERSITY OF TEXAS MEDICAL SCHOOL AT HOUSTON
Class of 1993
Research & Publications (20)
Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities.
PMID 19650713·Antioxid Redox Signal·2010
6-review
Vascular and neural dysfunctions in obese Zucker rats: effect of AVE7688.
PMID 19536347·Exp Diabetes Res·2009
7-preclinical
Treatment of Zucker diabetic fatty rats with AVE7688 improves vascular and neural dysfunction.
PMID 18564175·Diabetes Obes Metab·2009
7-preclinical
Attenuation of vascular/neural dysfunction in Zucker rats treated with enalapril or rosuvastatin.
PMID 18223617·Obesity (Silver Spring)·2008
7-preclinical
The potential role of angiotensin converting enzyme and vasopeptidase inhibitors in the treatment of diabetic neuropathy.
PMID 18220715·Curr Drug Targets·2008
6-review
Impaired responsiveness of renal sensory nerves in streptozotocin-treated rats and obese Zucker diabetic fatty rats: role of angiotensin.
PMID 18199587·Am J Physiol Regul Integr Comp Physiol·2008
7-preclinical
Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction.
PMID 18183531·Curr Opin Investig Drugs·2008
6-review
Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes.
PMID 18164667·Vascul Pharmacol·2008
7-preclinical
Vascular and neural dysfunction in Zucker diabetic fatty rats: a difficult condition to reverse.
PMID 17970755·Diabetes Obes Metab·2008
7-preclinical
Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats.
PMID 17911342·Am J Physiol Endocrinol Metab·2007
7-preclinical
Treatment of streptozotocin-induced diabetic rats with AVE7688, a vasopeptidase inhibitor: effect on vascular and neural disease.
PMID 17259379·Diabetes·2007
7-preclinical
Poly(ADP-ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy.
PMID 16731831·Diabetes·2006
7-preclinical
Progression of coronary and mesenteric vascular dysfunction in Zucker obese and Zucker diabetic fatty rats.
PMID 16714356·Am J Physiol Heart Circ Physiol·2006
7-preclinical
ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats.
PMID 16443766·Diabetes·2006
7-preclinical
Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited.
PMID 16306359·Diabetes·2005
7-preclinical
Progression of vascular and neural dysfunction in sciatic nerves of Zucker diabetic fatty and Zucker rats.
PMID 15727946·Am J Physiol Endocrinol Metab·2005
4-observational
Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications.
PMID 15616034·Diabetes·2005
7-preclinical
CCK-A receptor induction and P38 and NF-kappaB activation in acute pancreatitis.
PMID 14988658·Pancreatology·2004
7-preclinical
Preventing superoxide formation in epineurial arterioles of the sciatic nerve from diabetic rats restores endothelium-dependent vasodilation.
PMID 12653215·Free Radic Res·2003
7-preclinical
The role of oxidative stress in diabetic vascular and neural disease.
PMID 12797466·Free Radic Res·2003
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 8595 PICARDY AVE, STE 100
BATON ROUGE, LA 70809 - Phone
- (225) 763-4900
Quick Facts
- NPI
- 1225030737
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 33
- Publications
- 20
Are you this provider?
Claim Your Profile